The new labeled heterodimer provided high contrast PET and SPECT images of PSMA/GRPR-positive xenografts shortly after administration (1–3 h) due to rapid blood clearance, high tumor uptake, and low uptake in normal tissues and excretory organs, including PSMA-expressing kidneys (Figure 4). This evidence concerns the gene FOLH1 and neoplasm.